Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year The 10 Best Stocks to Own in 2023 7 Stocks to Buy and Hold Forever Vaso Corporation, together with its subsidiaries, operates in the healthcare ...

Vaso Corporation PLAINVIEW, N.Y., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading medtech company with a diversified business portfolio in network and ...

The majority of SCD patients given Lyfgenia in clinical trials remained free of vaso-occlusive events (VOEs) following ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Bluebird Bio (BLUE) announced new and updated data from LYFGENIA gene therapy for patients with sickle cell disease who have a history of ...

Without adopting new methods of construction and materials it won't be able to rebuild Britain at the pace outlined in the ...

Cabernet Sauvignon, native to Bordeaux, has thick blue skins, giving the resulting wines plentiful tannins and phenolics and making them particularly ageworthy. Over the past 50 years, Cabernet ...

Shares of Vaso Corporation VASO have gained 0.3% since the company reported its earnings for the quarter ended Sept. 30, 2024. This compares with the S&P 500 index’s -2% change over the same time ...